• Mashup Score: 0
    GI snapshot: weight loss and altered bowel habit in a 72-year-old woman - 6 month(s) ago

    A 72-year-old woman presented with a 9-month history of alternating constipation and diarrhoea, with postprandial abdominal pain. She noted constitutional symptoms of weight loss, decreased appetite and night sweats. This occurred on a background of systemic lupus erythematosus (SLE), treated with 200 mg twice daily hydroxychloroquine and 10 mg daily prednisolone. She appeared cachectic with significant muscle wasting. Abdominal examination revealed diffuse tenderness on deep palpation, with no appreciable mass or lymphadenopathy. White cell count was 12.6×109/L (ref range: 4.0–11.0), platelet 580×109/L (ref range: 150–400), C reactive protein 149 mg/L (ref range: <5), erythrocyte sedimentation rate 91 mm/hour (ref range: <20). Tumour markers were within normal range. Rheumatological screening revealed an antinuclear antibody titre of 1:160, while dsDNA (ELISA) (59 IU/mL, ref range: <100) …

    Source: gut.bmj.com
    Categories: Gastroenterology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Gut_BMJ
      Gut_BMJ

      Read the latest #GISnapshot #GUTSnapshot by Lin et al from @StVincentsMelb entitled "GI snapshot: weight loss and altered bowel habit in a 72-year-old woman" via https://t.co/LQYqYcCLMF #RheumTwitter #GITwitter https://t.co/mFNJSRyBaW

  • Mashup Score: 1
    FDA clears third IND for Kyverna’s CAR T-cell drug to treat systemic sclerosis - 6 month(s) ago

    The FDA has approved an investigational new drug application for Kyverna Therapeutics’ KYV-101, an anti-CD19 chimeric antigen receptor T-cell therapy for diffuse cutaneous systemic sclerosis, according to a company press release.The FDA decision marks the third IND clearance for KYV-101, following earlier authorizations for lupus nephritis and B cell-driven autoimmune diseases. Kyverna is

    Source: www.healio.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of HealioRheum
      HealioRheum

      Is competition heating up in the CD19-CAR T-cell space?🔥 ✳️@KyvernaT's KYV-101 snags FDA clearance for #scleroderma just days after @CabalettaBio's CABA-201 -- what's coming next? #RheumTwitter Read more🔽https://t.co/BFNtK8NyjW

  • Mashup Score: 3
    Efficacy and Safety of Tofacitinib in Anti–Melanoma... : JCR: Journal of Clinical Rheumatology - 6 month(s) ago

    were treated with tofacitinib and followed up. Clinical and laboratory data of these patients were recorded between January 2019 and June 2022. SPSS was used for all statistical analyses. Results The mean age of patients with MDA5+DM was 45 ± 12.4 years, and the median disease duration was 6.5 months (range, 3–13 months). The mean dosage of glucocorticoids was 34.7 ± 20.9 mg/d at the initiation of tofacitinib therapy. Overall, 47 patients were followed up for a mean duration of 7.8 ± 6.2 months. We found that the clinical symptoms of 28 patients (59.6%) were improved, but 1 patient (2.1%) died because of severe infection. Moreover, complications occurred in 25 patients (53.2%), among whom 19 patients had infections. Older age and C-reactive protein levels close to the upper value in reference range at the initial treatment were found to be the potential risk factors of infection. Furthermore, patients with cutaneous ulcers were found to have a lower risk of infection. Conclusion Tofaci

    Source: journals.lww.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of JRheumatology
      JRheumatology

      Efficacy and safety of tofacitinib for the treatment of anti-MDA5 antibody-positive #Dermatomyositis https://t.co/D5R6QATW1f #Rheumtwitter #Myositis

  • Mashup Score: 1
    Disease-Modifying Antirheumatic Drug Use and Its Effect on... : JCR: Journal of Clinical Rheumatology - 6 month(s) ago

    Methods This cohort study included Medicare beneficiaries with diagnosis of RA who received at least 30-day consecutive prescription of opioids in 2017 (n = 23,608). The patients were grouped into non-DMARD and DMARD users, who were further subdivided into regimens set forth by the American College of Rheumatology. The outcome measured was long-term opioid use in 2018 defined as at least 90-day consecutive prescription of opioids. Dose and duration of opioid use were also assessed. A multivariable model identifying factors associated with non-DMARD use was also performed. Results Compared with non-DMARD users, the odds of long-term opioid use were significantly lower among DMARD users (odds ratio, 0.89; 95% confidence interval, 0.83–0.95). All regimens except non–tumor necrosis factor biologic + methotrexate were associated with lower odds of long-term opioid use relative to non-DMARD users. The mean total morphine milligram equivalent, morphine milligram equivalent per day, and total

    Source: journals.lww.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of JRheumatology
      JRheumatology

      Effect of Disease-Modifying Anti-Rheumatic Drugs on long-term opioid use in patients with RA. https://t.co/W8BRFkFFoS #Rheumtwitter #Rheumatoid

Load More